Clinical trial · Observational
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer ( SENTIVUC II)
NCT06161428CI-TRIAL-00072203SENTIVUC IIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the feasibility of applying the SLN mapping technique in combination with FDG-PET/CT imaging in women with vulva cancer tumour size \>4 cm, multifocal tumors and local recurrences.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sentinel Lymph Node | — | UNRESOLVED | — |
| Vulva Cancer | Vulvar Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Sensitivity
- timeFrame
- Three years
- description
- Sensitivity of sentinel lymph node mapping
Secondary outcomes (1)
- measure
- Negative predictive value
- timeFrame
- Three years
- description
- Negative predictive value of sentinel lymph node mapping
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with vulva cancer, tumor \> 4 cm, multifocal tumor, or local recurrences in vulva Exclusion Criteria: * Previous external irradiation of the vulva or groins * Former sentinel node or inguinal lymphadenectomy in the relevant groin * Known allergy to ICG or iodine * Patient is in active treatment for other cancer and/or disseminated disease
References
Publications (0)
Data not yet available
No reference posted for this study.